{"id":71734,"date":"2026-08-05T14:44:13","date_gmt":"2026-08-05T06:44:13","guid":{"rendered":"https:\/\/flcube.com\/?p=71734"},"modified":"2026-08-05T14:44:14","modified_gmt":"2026-08-05T06:44:14","slug":"curium-pharma-to-acquire-lantheus-holdings-in-8-billion-deal-expanding-radiopharmaceutical-market-dominance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71734","title":{"rendered":"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Curium Pharma<\/strong>, a private equity-backed radiopharmaceutical company, has agreed to acquire peer <strong>Lantheus Holdings<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/LNTH:NASDAQ\">NASDAQ: LNTH<\/a>) in a transaction valued at <strong>up to USD 8 billion<\/strong>, as the firm seeks to significantly expand its footprint in the fast-growing radiopharmaceutical sector. Under the agreement, <strong>Lantheus shareholders will receive USD 102.50 per share in cash<\/strong> upon deal closure, plus <strong>contingent value rights (CVRs) worth up to USD 12 additional per share<\/strong> if certain sales targets are achieved by 2030.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Curium Pharma (private equity-backed)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Lantheus Holdings (NASDAQ: LNTH)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to USD 8 billion<\/td><\/tr><tr><td><strong>Base Consideration<\/strong><\/td><td>USD 102.50 per share in cash<\/td><\/tr><tr><td><strong>Contingent Consideration<\/strong><\/td><td>Up to USD 12.00 per share (CVRs tied to 2030 sales targets)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>03 Aug 2026 (Monday)<\/td><\/tr><tr><td><strong>Market Reaction<\/strong><\/td><td>Lantheus shares rose &gt;2% in morning trading<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-context\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sector Consolidation<\/strong>: Transaction represents significant consolidation in the specialized radiopharmaceutical market<\/li>\n\n\n\n<li><strong>Growth Trajectory<\/strong>: Radiopharmaceutical sector experiencing accelerated growth driven by advances in nuclear medicine and diagnostic imaging<\/li>\n\n\n\n<li><strong>Complementary Portfolios<\/strong>: Combined entity will benefit from expanded product portfolio spanning diagnostic and therapeutic radiopharmaceuticals<\/li>\n\n\n\n<li><strong>Geographic Synergies<\/strong>: Enhanced global reach through combined distribution networks and manufacturing capabilities<\/li>\n\n\n\n<li><strong>Private Equity Strategy<\/strong>: Demonstrates continued investor confidence in specialized pharmaceutical segments with high barriers to entry<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-structure-amp-valuation\" class=\"wp-block-heading\">Financial Structure &amp; Valuation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enterprise Value<\/strong>: Approximately USD 8 billion including contingent considerations<\/li>\n\n\n\n<li><strong>Premium Analysis<\/strong>: Base offer of USD 102.50 represents significant premium to pre-announcement trading levels<\/li>\n\n\n\n<li><strong>Earn-out Mechanism<\/strong>: CVRs provide upside participation for shareholders while managing acquirer risk<\/li>\n\n\n\n<li><strong>Funding Structure<\/strong>: Backed by private equity sponsors with proven track record in healthcare investments<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Expected to require standard antitrust and regulatory approvals given specialized nature of radiopharmaceutical market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-implications\" class=\"wp-block-heading\">Competitive Landscape Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Leadership<\/strong>: Combined entity positioned as leading pure-play radiopharmaceutical company globally<\/li>\n\n\n\n<li><strong>Scale Advantages<\/strong>: Enhanced manufacturing scale, R&amp;D capabilities, and commercial infrastructure<\/li>\n\n\n\n<li><strong>Pipeline Acceleration<\/strong>: Increased resources to advance development pipeline across diagnostic and therapeutic applications<\/li>\n\n\n\n<li><strong>Customer Base Expansion<\/strong>: Broader product offering to serve nuclear medicine departments and imaging centers<\/li>\n\n\n\n<li><strong>Supply Chain Security<\/strong>: Strengthened position in critical isotope supply chain management<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-integration-outlook\" class=\"wp-block-heading\">Forward Integration Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Timeline<\/strong>: Expected to close in H1 2027 pending customary approvals<\/li>\n\n\n\n<li><strong>Integration Strategy<\/strong>: Focus on operational synergies while maintaining product quality and supply continuity<\/li>\n\n\n\n<li><strong>Workforce Impact<\/strong>: Limited expected redundancies given complementary nature of operations<\/li>\n\n\n\n<li><strong>Customer Communication<\/strong>: Commitment to uninterrupted product supply during transition period<\/li>\n\n\n\n<li><strong>Market Positioning<\/strong>: Enhanced ability to compete with larger diversified pharmaceutical companies entering radiopharmaceutical space<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding transaction completion, regulatory approvals, and strategic benefits. Actual outcomes may differ due to risks including regulatory decisions, financing conditions, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4761],"class_list":["post-71734","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-curium-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ: LNTH) in a transaction valued at up to USD 8 billion, as the firm seeks to significantly expand its footprint in the fast-growing radiopharmaceutical sector. Under the agreement, Lantheus shareholders will receive USD 102.50 per share in cash upon deal closure, plus contingent value rights (CVRs) worth up to USD 12 additional per share if certain sales targets are achieved by 2030.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71734\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance\" \/>\n<meta property=\"og:description\" content=\"Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ: LNTH) in a transaction valued at up to USD 8 billion, as the firm seeks to significantly expand its footprint in the fast-growing radiopharmaceutical sector. Under the agreement, Lantheus shareholders will receive USD 102.50 per share in cash upon deal closure, plus contingent value rights (CVRs) worth up to USD 12 additional per share if certain sales targets are achieved by 2030.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71734\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T06:44:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T06:44:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71734#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71734\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance\",\"datePublished\":\"2026-08-05T06:44:13+00:00\",\"dateModified\":\"2026-08-05T06:44:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71734\"},\"wordCount\":440,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Curium Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71734#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71734\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71734\",\"name\":\"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-05T06:44:13+00:00\",\"dateModified\":\"2026-08-05T06:44:14+00:00\",\"description\":\"Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ: LNTH) in a transaction valued at up to USD 8 billion, as the firm seeks to significantly expand its footprint in the fast-growing radiopharmaceutical sector. Under the agreement, Lantheus shareholders will receive USD 102.50 per share in cash upon deal closure, plus contingent value rights (CVRs) worth up to USD 12 additional per share if certain sales targets are achieved by 2030.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71734#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71734\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71734#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance - Insight, China&#039;s Pharmaceutical Industry","description":"Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ: LNTH) in a transaction valued at up to USD 8 billion, as the firm seeks to significantly expand its footprint in the fast-growing radiopharmaceutical sector. Under the agreement, Lantheus shareholders will receive USD 102.50 per share in cash upon deal closure, plus contingent value rights (CVRs) worth up to USD 12 additional per share if certain sales targets are achieved by 2030.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71734","og_locale":"en_US","og_type":"article","og_title":"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance","og_description":"Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ: LNTH) in a transaction valued at up to USD 8 billion, as the firm seeks to significantly expand its footprint in the fast-growing radiopharmaceutical sector. Under the agreement, Lantheus shareholders will receive USD 102.50 per share in cash upon deal closure, plus contingent value rights (CVRs) worth up to USD 12 additional per share if certain sales targets are achieved by 2030.","og_url":"https:\/\/flcube.com\/?p=71734","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T06:44:13+00:00","article_modified_time":"2026-08-05T06:44:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71734#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71734"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance","datePublished":"2026-08-05T06:44:13+00:00","dateModified":"2026-08-05T06:44:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71734"},"wordCount":440,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Curium Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71734#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71734","url":"https:\/\/flcube.com\/?p=71734","name":"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-05T06:44:13+00:00","dateModified":"2026-08-05T06:44:14+00:00","description":"Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ: LNTH) in a transaction valued at up to USD 8 billion, as the firm seeks to significantly expand its footprint in the fast-growing radiopharmaceutical sector. Under the agreement, Lantheus shareholders will receive USD 102.50 per share in cash upon deal closure, plus contingent value rights (CVRs) worth up to USD 12 additional per share if certain sales targets are achieved by 2030.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71734#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71734"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71734#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71734"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71734\/revisions"}],"predecessor-version":[{"id":71736,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71734\/revisions\/71736"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}